期刊
SCIENTIFIC REPORTS
卷 8, 期 -, 页码 -出版社
NATURE RESEARCH
DOI: 10.1038/s41598-018-19549-x
关键词
-
资金
- UK Biotechnology and Biological Sciences Research Council [BB/F008228/1]
- Bill and Melinda Gates foundation [Op1087646]
- Sao Paulo Research Foundation - FAPESP [2012/23306-5, 2015/19103-0, 2015/03553-6]
- ERC [208813]
- European Commission under the FP7 Collaborative Programme, UNICELLSYS
- European Research Council (ERC) [208813] Funding Source: European Research Council (ERC)
- Biotechnology and Biological Sciences Research Council [BB/F008228/1] Funding Source: researchfish
- BBSRC [BB/F008228/1] Funding Source: UKRI
Malaria, caused by parasites of the genus Plasmodium, leads to over half a million deaths per year, 90% of which are caused by Plasmodium falciparum. P. vivax usually causes milder forms of malaria; however, P. vivax can remain dormant in the livers of infected patients for weeks or years before re-emerging in a new bout of the disease. The only drugs available that target all stages of the parasite can lead to severe side effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; hence, there is an urgent need to develop new drugs active against blood and liver stages of the parasite. Different groups have demonstrated that triclosan, a common antibacterial agent, targets the Plasmodium liver enzyme enoyl reductase. Here, we provide 4 independent lines of evidence demonstrating that triclosan specifically targets both wild-type and pyrimethamine-resistant P. falciparum and P. vivax dihydrofolate reductases, classic targets for the blood stage of the parasite. This makes triclosan an exciting candidate for further development as a dual specificity antimalarial, which could target both liver and blood stages of the parasite.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据